Clinical Trials Logo

Pigmentary Glaucoma clinical trials

View clinical trials related to Pigmentary Glaucoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT05231928 Recruiting - Pigmentary Glaucoma Clinical Trials

A Novel Argon Laser Iridoplasty for Pigment Dispersion Syndrome

Start date: December 1, 2021
Phase: N/A
Study type: Interventional

Pigment dispersion syndrome is a rare condition where anomalous iris configuration leads to posterior iris bowing with subsequent friction with the lenticulozonular unit resulting in dispersion of pigment from the back surface of the iris into the anterior segment as well as thinning with resultant transillumination defects in the mid iris segment. The released pigment is deposited in various parts of the anterior segment resulting in a constellation of clinical signs: Krukenberg Spindle: Back surface of the cornea Zentmayer ring: Back surface of the lens. Egger line: Anterior vitreous face. More importantly, pigment accumulated in the trabecular meshwork leading to visible hyperpigmentation of the trabeculum seen by gonioscopy. This leads to reduction of aqueous outflow which leads to ocular hypertension or even glaucoma which is known as pigment dispersion glaucoma which is considered one of refractory glaucomas. Current practice in the management of pigment dispersion syndrome revolves around the management of glaucoma when it develops by IOP lowering medication, Laser trabeculoplasty or peripheral iridoplastyor glaucoma surgery as a last resort. The only prophylactic measure in practice that is aimed at preventing the progression from mere pigment dispersion to pigment dispersion glaucoma is the long term use of miotic eyedrops e.g. Pilocarpine which comes with both risks and side effects i.e. the risk of retinal breaks and detachment which is even higher in a cohort which is predominantly myope, the constriction of visual field and ocular surface complications. In this interventional case series, the investigators assess the efficacy of a novel Argon Laser iridoplasty in the management of pigment dispersion through correcting the posterior iris bowing and hence halting the dispersion process so that glaucoma wouldn't develop in the first place instead of managing glaucoma after it sets in which proved refractory.

NCT ID: NCT04202510 Withdrawn - Open Angle Glaucoma Clinical Trials

IOP and Medication Reduction in MIGS Procedures

Start date: January 6, 2020
Phase: N/A
Study type: Interventional

The primary objective of this research is to compare the efficacy of trabecular minimally invasive glaucoma surgery (MIGS) devices (iStent vs iStent Inject vs Hydrus) for intra ocular pressure (IOP) and anti-glaucoma medication reduction in open angle glaucoma.

NCT ID: NCT02355990 Completed - Clinical trials for Primary Open Angle Glaucoma

Minimally Invasive Micro Sclerostomy First in Man Safety and Preliminary Performance Study

Start date: February 1, 2015
Phase: N/A
Study type: Interventional

The study objective is to demonstrate the safety of Minimally Invasive Micro Sclerostomy (MIMS) device for lowering elevated IOP in patients diagnosed with glaucoma.

NCT ID: NCT02023242 Completed - Clinical trials for Primary Open Angle Glaucoma

Comparing Effectiveness of the Hydrus Microstent (TM) to Two iStents to Lower IOP in Phakic Eyes

COMPARE
Start date: October 2012
Phase: N/A
Study type: Interventional

This clinical trial compares two implantable devices intended to lower the pressure inside the eye of glaucoma patients.

NCT ID: NCT01767753 Completed - Clinical trials for Primary Open Angle Glaucoma

IOP Fluctuations in Patients With Primary Open-angle Glaucoma, Before and After Selective Laser Trabeculoplasty

Start date: November 2012
Phase: N/A
Study type: Interventional

Selective laser trabeculoplasty (SLT) is an increasingly popular treatment modality in early-to-moderate glaucoma patients. SLT has been suggested to reduce IOP more consistently during the nocturnal period than during the diurnal period in a group of medically-treated patients with primary open angle glaucoma (POAG). At present, there is scarce data on SLT effects on the 24-hour IOP pattern in patients with glaucoma and there is no data on the 24-hour effect of SLT in untreated glaucoma patients. The purpose of this study is to assess the changes of IOP over a 24-hour period in patients with glaucoma undergoing SLT.

NCT ID: NCT01301378 Terminated - Clinical trials for Primary Open Angle Glaucoma

Patch Graft Material Safety and Effectiveness in Covering Glaucoma Drainage Device Tube

Start date: August 2010
Phase: N/A
Study type: Interventional

The investigators hypothesize that KeraSys is a safe as Tutoplast to cover the tube of the Molteno 3 glaucoma drainage device during surgery

NCT ID: NCT00441883 Completed - Ocular Hypertension Clinical Trials

Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma

Start date: March 2007
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety and efficacy of PF 03187207.

NCT ID: NCT00280345 Completed - Cataract Clinical Trials

Autoimmune Dysregulation in Pigmentary Glaucoma

Start date: February 2006
Phase: N/A
Study type: Interventional

Based on these recent observations and findings in this new animal model of pigmentary glaucoma in the DBA/2J mouse, we propose that immune system abnormalities in the anterior chamber may play a possible role in the development of pigmentary glaucoma and possibly primary open-angle glaucoma (POAG) in humans.